High-dose ifosfamide has been identified as a preferred therapy for relapsing-remitting Ewing sarcoma in a phase 3 trial that associated this treatment with an overall survival (OS) advantage, despite more discontinuations due to toxicity. The findings were presented at the 2022 annual meeting of the American Society of Clinical Oncology (ASCO).
The study compared two arms for the primary end point after discontinuing two other arms for lack of promise, but future study arms are planned to